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Summary
Muscle stem (satellite) cells are relatively resistant to cell-
autonomous aging. Instead, their endogenous signaling
proﬁle and regenerative capacity is strongly inﬂuenced
by the aged P-Smad3, differentiated niche, and by the
aged circulation. With respect to muscle ﬁbers, we previ-
ously established that a shift from active Notch to exces-
sive transforming growth factor-beta (TGF-b) induces CDK
inhibitors in satellite cells, thereby interfering with pro-
ductive myogenic responses. In contrast, the systemic
inhibitor of muscle repair, elevated in old sera, was sug-
gested to be Wnt. Here, we examined the age-dependent
myogenic activity of sera TGF-b1, and its potential cross-
talk with systemic Wnt. We found that sera TGF-b1
becomes elevated within aged humans and mice, while
systemic Wnt remained undetectable in these species.
Wnt also failed to inhibit satellite cell myogenicity, while
TGF-b1 suppressed regenerative potential in a biphasic
fashion. Intriguingly, young levels of TGF-b1 were inhibi-
tory and young sera suppressed myogenesis if TGF-b1
was activated. Our data suggest that platelet-derived sera
TGF-b1 levels, or endocrine TGF-b1 levels, do not explain
the age-dependent inhibition of muscle regeneration by
this cytokine. In vivo, TGF-b neutralizing antibody, or a
soluble decoy, failed to reduce systemic TGF-b1 and rescue
myogenesis in old mice. However, muscle regeneration
was improved by the systemic delivery of a TGF-b receptor
kinase inhibitor, which attenuated TGF-b signaling in skel-
etal muscle. Summarily, these ﬁndings argue against the
endocrine path of a TGF-b1-dependent block on muscle
regeneration, identify physiological modalities of age-
imposed changes in TGF-b1, and introduce new thera-
peutic strategies for the broad restoration of aged organ
repair.
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Introduction
Adult skeletal muscle robustly regenerates throughout an
organism’s life but, with advancing age, its ability to repair
diminishes and ultimately fails (Grounds, 1998; Renault et al.,
2002). Muscle satellite cells play a crucial role in this regenerative
process, and are physically situated beneath the basal lamina of
myoﬁbers (i.e. differentiated muscle cells) (Mauro, 1961). Upon
myoﬁber damage, quiescent satellite cells become activated and
begin proliferating as myogenic progenitor cells, which later dif-
ferentiate into fusion-competent myoblasts and de novo multi-
nucleated myoﬁbers (Collins et al., 2005; Wagers & Conboy,
2005). Although diminished satellite cell numbers have been
implicated in the age-related decline of muscle tissue regenera-
tion, several reports identiﬁed key molecular changes within
Notch and P-Smad3 signaling in the aged endogenous popula-
tions (Conboy et al., 2003; Carlson & Conboy, 2007b; Carlson
et al., 2008). In this regard, aging of the satellite cell micro-niche
was found to promote underproduction of Notch ligand Delta,
and overproduction of transforming growth factor-beta (TGF-b).
Consequently, satellite cells residing in old muscle ﬁbers express
excessive levels of CDK inhibitors, and thus fail to break quies-
cence and proliferate in response to injury. However, the regen-
erative responses of aged satellite cells can be rescued, either by
forced activation of Notch, or by shRNA targeting of Smad3
(Schultz & Lipton, 1982; Conboy et al., 2003; Carlson et al.,
2008). The regenerative capacity of aged muscle can also be
enhanced by exposing old satellite cells to young systemic
factors – such as when young and old mice are physically
connected to share blood circulation (parabiosis), or when aged
satellite cells are cultured in the presence of young sera (Conboy
et al., 2005; Carlson & Conboy, 2007a). This improved regener-
ation of aged muscle is due to the enhanced activity of endo-
genous aged satellite cells, and not from physical contributions
of young cells within the common circulation (Conboy et al.,
2005). Therefore, in addition to local tissue niches, systemic
factors in sera also regulate the regenerative responses of organ
stem cells and importantly, the aged circulation inhibits the
regenerative potential of even young satellite cells (Carlson &
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lFaulkner, 1989; Brack & Rando, 2007; Carlson & Conboy,
2007a). This evidence suggests, in the case of hetero-
chronic parabiosis, the inhibitory factors introduced into shared
circulation by old partners were continuously removed, or func-
tionally neutralized, by the young partners.
It was reported that the aged circulation inhibits satellite cell
responses by acting through the Wnt pathway (Brack et al.,
2007). These ﬁndings raised particular interest, as Wnt proteins
are not known to be endocrine in nature, and Wnt signaling
was recently demonstrated to enhance myogenic proliferation
and differentiation in both embryonic and adult development
(Ikeya & Takada, 1998; Marom et al., 1999; Wagner et al.,
2000; Shi et al., 2002; Brack et al., 2008; Le Grand et al.,
2009). A recent study from our laboratory implicated the TGF-b
family in the local inhibition of aged satellite cell responses
(Carlson et al., 2008). We therefore decided to explore a poten-
tial age-dependent endocrine activity of TGF-b, and its potential
cross-talk with Wnt. Moreover, we extrapolated our previous
ﬁndings by narrowing down the anti-myogenic inhibitory
activity to one TGF-b family member, namely TGF-b1 (Li et al.,
2004; Shen et al., 2008).
Transforming growth factor-beta proteins are multifunctional
cytokines, secreted by numerous cell types. They are capable of
signaling to virtually every cell type and broadly control cell pro-
liferation, differentiation, apoptosis, inﬂammation and scarring
in various tissues (Massague, 1998; Massague & Chen, 2000;
Derynck & Zhang, 2003). TGF-b ligands are synthesized by cells
and secreted as precursor complexes that are composed of
mature dimeric C-terminal polypeptides; speciﬁcally, the latency
associated propeptide and the latent TGF-b binding protein
(LTBP) (Annes et al., 2003; Hyytiainen et al., 2004). These com-
plexes can be transported in the blood, and are normally tar-
geted to tissue extracellular matrix by the appropriate LTBP,
where the mature polypeptide is cleaved. These activated
ligands are then capable of binding to their speciﬁc receptors,
thereby initiating TGF-b⁄P-Smad signal transduction. Several
validated small molecule inhibitors, which speciﬁcally interfere
with TGF-b receptor I kinase activity, are capable of blocking
Smad phosphorylation upon receptor I ligand binding (Singh
et al., 2003; Gellibert et al., 2004). Similarly, an exogenous
dominant-negative form of TGF-b receptor II has been shown to
effectively prevent TGF-b signaling in several cell types (Brand
et al., 1993; Tang et al., 1999). Both active and inactive TGF-b
proteins are found in sera (Assoian et al., 1983; Massague,
1987), whereby inactive TGF-b, transported in blood plasma, is
available for activation locally in tissues. In this regard, blood
cells (mostly platelets and CD4
+ T lymphocytes) are known to
produce and release high levels of total and biologically-active
TGF-b ligands (Assoian et al., 1983). Considering the strong
morphogenic properties of TGF-b, changes in the levels of either
total (latent plus active) or active form alone, are likely to inﬂu-
ence immune responses, tissue maintenance and regeneration.
The results shown here argue against the notion of systemic
TGF-b1 endocrine activity and strongly suggest that TGF-b,
released by the known process of platelet activation during sera
collection, inhibits satellite cell responses in vitro. These ﬁndings
also suggest that young sera may contain a functional and
natural decoy of TGF-b1, or a competitor of TGF-b1 signaling
pathway (either endocrine or released by platelets). Lastly, our
results demonstrate that Wnt antagonizes, rather than synergiz-
es with TGF-b1-mediated satellite cell response inhibition.
Results
Deﬁning the inhibitory range of systemic TGF-b1
The TGF-b family is composed of roughly 35 different ligands. In
addition to other cytokines (e.g. IGF-1, TNF-a, IL-6, etc.) many of
these have been implicated in the process of aging, and with
respect to muscle regeneration (Grounds, 2002; Moresi et al.,
2008; Dorshkind et al., 2009). Here, we focused on ﬁrst
determining whether the aged circulation is inhibitory to
adult myogenesis through the activity of one particular family
member – TGF-b1.
We speciﬁcally postulated that TGF-b1 levels of young sera
are benign or positive to myogenic regulation, while TGF-b1
levels found in aged circulation are inhibitory. To explore this,
we ﬁrst depleted TGF-b1 from young and old mouse serum, fol-
lowed by re-addition at a range of tested concentrations. Muscle
stem cells, derived from young and old mice, were then cultured
in the presence of young and old TGF-b1-depleted, or modiﬁed,
mouse serum. The regenerative responses of these cells were
assayed, in vitro. Sera was depleted of TGF-b1 by incubation
with a TGF-b1-speciﬁc antibody (or isotype-matched control
IgG), followed by removal of the TGF-b1–antibody complexes
(or control IgG antibody complexes) using protein G-coated aga-
rose beads. The success of TGF-b1 depletion was also conﬁrmed
by ELISA (not shown). Muscle stem cell myogenic regenerative
potential was quantiﬁed, based on their ability to generate
de-novo myogenic lineages – i.e. BrdU-incorporating desmin
+
myoblasts (myogenic proliferation) that differentiate into post-
mitotic eMyHC
+ myotubes (myogenic differentiation) (Conboy
et al., 2003, 2005; Sherwood et al., 2004). The time course of
such de-novo in vitro myogenesis recapitulates in vivo muscle
repair (Conboy & Rando, 2002; Conboy et al., 2005), and is
shown in Supporting Fig. S1A–D. In agreement with previous
ﬁndings (Carlson & Conboy, 2007a), myogenic proliferation
(24–48 h of culture) and myogenic differentiation (48–72 h of
culture) were consistently higher for young satellite cells and in
young serum at all time points, compared to old (Figs 1 and
S1A–D). Nonmyogenic, desmin
) proliferating ﬁbroblasts were
less numerous in cultures with experimentally calibrated levels
of TGF-b1 (Fig. 1), and also declined in cultures with exogenous
Wnt3A addition (Fig. 3, below). These cells are known to
contaminate satellite cell preparations at 2–5%, and to
expand in the presence of old serum or high levels of TGF-b
(Carlson et al., 2008).
Very interestingly, the productive myogenic proliferation of
young and old muscle stem cells was robust in TGF-b1-depleted
serum, only when low levels of recombinant TGF-b1 were intro-
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677(A) (B)
(C)
Fig. 1 Old sera inhibits satellite cell responses by
transforming growth factor (TGF)-b-dependent
mechanism. Young (A) and old (B) myoﬁber-
associated myogenic progenitor cells were isolated
3 days postinjury and cultured overnight in Opti-
MEM containing either 10% young serum (YS),
10% old (OS), TGF-b1 antibody depleted serum
alone, or with ﬁxed amounts of recombinant
TGF-b1 in the culture system. Cells were cultured
with their speciﬁc sera for 24 h, and transferred to
differentiation medium for additional 48 h (Fig S2).
BrdU was added for the last 2 h to measure
proliferation. Cells were then ﬁxed and
immunostained for desmin (green) and BrdU (red),
with Hoechst (blue) marking all nuclei (as shown in
C), and scored in multiple random ﬁelds from the
above assays. Results are displayed as the mean
percent of Desmin
+⁄ BrdU
+ ⁄total cells, ±SD.
*P < 0.05 for isochronic Y+YS ⁄O+OS 0 ng mL
)1,
compared to 0.5 ng mL
)1, and 5.0 ng mL
)1
compared to 0.5 ng mL
)1; n =3 .
(A)
(C)
(B)
(D)
Fig. 2 Transforming growth factor (TGF)-b1 levels become elevated in old sera. (A) Mouse sera TGF-b1 becomes elevated with age. Mean serum levels, ±SEM, of
TGF-b1 in young (Ym) or old (Om, n = 12 for each) mice as determined by sandwich ELISA; P < 0.0001. (B) Human TGF-b1 serum levels become elevated with
age. TGF-b1 levels in the serum of aged humans (AG: 65–90 years old) vs. young (YG: 20–35 year old) were determined by ELISA. Error bars (SEM) represent the
mean of 53 different subjects in each group; P < 0.0001. Similar age-related elevations in TGF-b1 were detected by bioactivity assay (Fig. S3). Dot plots represent
separate animals (A) and separate individuals (D) of indicated ages. (C) Young and old myoﬁber explants were isolated at 3 days postinjury, and cultured overnight
in Opti-MEM containing either young or old serum alone (control), or serum that had undergone activation of total TGF-b alone, in combination with neutralizing
antibody to TGF-b1, or mixed with control serum. BrdU was added for the last 2 h to measure proliferation. Cells were ﬁxed and immunostained for desmin
(green) and BrdU (red), with Hoechst (blue) marking all nuclei (as shown in C, quantiﬁed in D). Cells were scored in multiple random ﬁelds and results are displayed
as the mean percent of Desmin
+ ⁄ BrdU
+ cells, ±SD. *P < 0.05 for activated compared to control, activated + antibody compared to activated, and control
compared to activate + control. n =3 .
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678duced (Fig. 1A–C). At 1–5 ng mL
)1 (and higher), TGF-b1 alone
sufﬁced for the inhibition of satellite cell responses, while myo-
genesis was positively regulated at 0.2 ng mL
)1 (Fig. 1A–C).
Similarly, myogenic differentiation responses from young cells
also peaked in TGF-b1-depleted serum, which received low lev-
els of exogenous recombinant TGF-b1 (Supporting Fig. S2A). In
contrast, old cell differentiation was improved by TGF-b1 deple-
tion from serum alone, as well as in a low range of recombinant
TGF-b1 addition (Supporting Fig. S2B). The overall differentia-
tion response from old cells was also diminished, compared to
young cells (Supporting Fig. S2A,B). As myogenic differentiation
was assayed at 48–72 h of culture, and aged satellite cells have
elevated TGF-b1 production (Carlson et al., 2008), these data
suggest that endogenous TGF-b1 production by old cells, in vi-
tro, counteracts the pro-myogenic effect of TGF-b1 depletion
from mouse serum (Figs 1, S1A–D and S2A,B).
Together, these data demonstrate that sera-derived TGF-b1
inhibits satellite cell responses, and that speciﬁc levels of TGF-b1
are required for productive myogenic responses. Even with com-
plete TGF-b1 depletion, old serum remained less myogenic than
(A) (B)
(C) (D)
(E) (F)
Fig. 3 Old serum inhibits satellite cell responses by a Wnt-independent mechanism. Bioactive human (A) and mouse (B) Wnt is undetectable in human or mouse
sera, and is not elevated with age. Human serum was collected from three young (20–25 years) and three old (65–75 years) individuals. Mouse serum was
collected from four young and four aged mice. Levels of biologically active Wnt were analyzed, using a Wnt-reporter expressing cell line. As compared to
recombinant Wnt3A, no detectable Wnt activity was found in either young or old serum. Raw ﬂuorescence values for young sera were marginally higher
compared to old sera, but both were not signiﬁcantly different from the negative control (no Wnt3a samples). Inset panel shows 0.1–10 ng mL
)1 Wnt3a range in
greater detail. Myoﬁber-associated myogenic progenitor cells were isolated 3 days postinjury and cultured overnight in Opti-MEM containing either (C) 10%
young serum (YS); YS+Wnt3A; YS+Wnt3A+TGF-b; or (E) 10% old (OS), OS+FRP3, OS+FRP3 + anti-TGF-b. BrdU was added for the last 2 h to measure
proliferation. Cells were then ﬁxed and immunostained for desmin (green) and BrdU (red), with Hoechst (blue) marking all nuclei. TGF-b addition reduced
myoblast and myotube production in young serum, TGF-b neutralization resulted in a much improved myogenic proliferation in old serum, and some cells even
formed de novo myotubes. In contrast, exogenous Wnt3A did not decrease myogenic responses in young serum and FRP3 did not rescue myogenic responses in
old serum. No synergy in regulation of myogenesis was detected between Wnt and TGF-b. (D) Quantiﬁcation of C. Cells were scored in multiple random ﬁelds
from the above assays and the results displayed as the mean percent of BrdU
+, desmin
+ ⁄total cells, ±SD. *P < 0.05 between young untreated or +Wnt3a vs.
+TGF-b or +TGF-b ⁄Wnt3a; **P < 0.05 for old ﬁbers, as described above for young. n = 3 for each set. (F) Quantiﬁcation of E. Cells were scored and displayed as
in E. *P < 0.05 between young ﬁbers + OS untreated or +FRP3 vs. +anti-TGF-b or +anti-TGF-b ⁄FRP3; **P < 0.05 for old ﬁbers as described for young ﬁbers;
n = 3 for each set.
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679young (by 10–20%), suggesting that while TGF-b1 is a main
inhibitor of satellite cell responses, it is not the only suppressor
of regeneration present in old sera (Figs 1A–C, S2A,B).
Correlating the inhibitory range of TGF-b1 with
physiological levels found in young and old sera
To further substantiate these conclusions, we correlated the
inhibitory range of TGF-b1 with its levels found in young vs.
aged sera. Speciﬁcally, we analyzed TGF-b1 levels as a function
of age in mice and in humans (Fig. 2A,B). In mice, TGF-b1 levels
sharply increased between 12 months (early postreproductive
age, analogous to 5th–6th decades in humans) and 24 months
(analogous to 8th–9th decades in humans), Fig. 2A. Moreover,
this systemic age-related rise was found to be conserved in
humans (Fig. 2B), where TGF-b1 plateaus at its highest systemic
levels between the 6th and 9th decades of life (i.e. roughly at
the onset and progression of age-imposed regenerative decline).
Sera TGF-b1 for both species thus becomes elevated from the
end of the reproductive period, to the end of lifespan.
Curiously, TGF-b1 levels in young mouse sera (100 ng mL
)1)
are predicted to be inhibitory to satellite cell responses (data
shown in Fig. 1), even if used at 5–10%, in vitro. Therefore,
despite apparent pro-myogenic differences between young and
old sera, physiological TGF-b1 levels alone do not explain the
inhibitory affects of aged sera on myogenic responses. To deter-
minewhethertheseinhibitoryaffectscorrelatedwithbiologically
active TGF-b1 levels, a bio-activity assay was performed on non-
activated serum samples, using the plasminogen activator inhibi-
tor-1 (PAI-1) promoter luciferase-reporter (Danielpour et al.,
1989; Abe et al., 1994), and by ELISA (Supporting Fig. S3C,D).
These data clearly demonstrated that while bioactive TGF-b1
was higher in old mouse serum, compared to young, the levels in
either sera were minute (> 4 ng mL
)1) and unlikely to be
inhibitory in the 5–10% range examined (Figs S3C,D and1).
Based on published literature, and in agreement with our
results, sera and plasma contain little-to-no active TGF-b1. How-
ever, the total TGF-b1 released by platelets during sera collection
becomes activated (e.g. by cells in culture), evoking an interplay
between positive and negative regulators that determines the
intracellular signaling strength. The platelet source of TGF-b1i n
our serum samples was corroborated, as expected (Supporting
Fig. S3E,F). We further postulated that, in the case of young
sera, TGF-b1 activity is attenuated and may therefore render
young sera pro-myogenic. To test this, we compared satellite
cell myogenic responses in cultures containing serum with (i)
endogenous TGF-b activity, (ii) forced-activated endogenous
TGF-b and (iii) forced-activated endogenous TGF-b, with subse-
quent TGF-b1-speciﬁc antibody neutralization. As shown in
Fig. 2C,D, young serum became inhibitory to satellite cell
responses (and similar in this regard to old sera) when endo-
genous young levels of TGF-b were forced-activated. Impor-
tantly, inhibition of myogenic activity was dependent on TGF-b1
and not related to sera-activation, as TGF-b1-speciﬁc neutraliza-
tion restored myogenicity to these cultures. Additionally, when
mixed with standard young serum, forced-activated young
serum was dominant in myogenic inhibition – suggesting that
the presence of negative regulators, rather than the removal of
positive regulators, accounts for such affects. These data
uncover that the strong inhibitory inﬂuence of aged sera (as
opposed to the pro-myogenic properties of young sera) are not
solely explained by age-related differences in TGF-b1 levels.
Correlation between systemic levels and myogenic
effects of Wnt
Using a luciferase-reporter assay (Kaykas et al., 2004; Brack
et al., 2007), we also measured the systemic levels of biologi-
cally active Wnt, since an age-dependent increase of circulating
Wnt (from 10 ng mL
)1 in young to 20 ng mL
)1 in old sera)
was recently reported (Brack et al., 2007). In our experiments,
Wnt was undetectable in young and old serum from both
humans and mice (Fig. 3A,B). Measurable levels of Wnt in all
samples were substantially < 5 ng mL
)1 (based on a recombi-
nant Wnt standard curve). Interestingly, the relative luciferase
activity values were actually higher for young mouse serum,
compared to old (Fig. 3B).
A rescue of satellite cell responses, in the presence of old
serum, was reported to be achieved by the inhibition of Wnt via
FRPs. In addition, exogenous Wnt3A was reported to inhibit
satellite cell myogenic responses, in favor of ﬁbroblast trans-
differentiation (Brack et al., 2007). We thus investigated
whether Wnt was potentially synergistic with the TGF-b1-
dependent attenuation of myogenic potential, and if Wnt sera
activity might be detected using satellite cell myogenicity assays.
To do so, the myogenic potential of young and old satellite cells
was examined in the presence of (i) young serum with exo-
genous Wnt3A (by itself, or simultaneously with exogenous
TGF-b1), or (ii) old serum with exogenous FRP3 (by itself, or
simultaneously with TGF-b neutralization). As shown in Fig. 3C–
F, exogenous FRP inhibition of Wnt did not rescue myogenic
responses in old serum. Moreover, exogenous Wnt3A did not
reduce myogenic potential in young serum. Consistent with a
reported pro-myogenic activity of Wnt (Brack et al., 2008),
Wnt3A also enhanced myotube formation (Supporting
Fig. S4A). However, in contrast to the induction of a ﬁbroblastic
cell fate (Brack et al., 2007), the presence of nonmyogenic ﬁbro-
blastic cells (e.g. desmin
)⁄BrdU
+) was not increased, but
reduced in the presence of exogenous Wnt3A, thereby further
validating the pro-myogenic activity of Wnt. Wnt modulation
also failed to synergize with the TGF-b1-promoted inhibition of
myogenic responses. In contrast, Wnt3A antagonized TGF-b1
and enhanced the generation of satellite cell-derived, fusion-
competent proliferating myoblasts (Fig. 4C–F). Additionally,
young satellite cells cultured with young serum had less active
GSK3b and more inactive GSK3b (compared to old satellite cells
cultured with old serum), suggesting that Wnt signaling is stron-
ger in young conditions (Supporting Fig. S4B,C). These ﬁndings
were also examined and conﬁrmed using single myoﬁber assays
(Brack et al., 2007 and Supporting Fig. S5). Combined, these
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680results further clarify the respective roles of Wnt and TGF-b1i n
adult myogenesis, demonstrate that Wnt activity is not present
in sera (determined by bioactivity and satellite cell myogenicity
assays), and also demonstrate that Wnt does not contribute to
the TGF-b1-dependent inhibition of satellite cell myogenic
potential.
Expression of a dominant-negative TGF-b receptor
restores productive myogenic responses to satellite
cells exposed to aged serum
After justifying our experimental focus on TGF-b1 as a myogenic
inhibitor, we decided to conﬁrm that (i) young sera, compared
to old, down-modulates TGF-b1 signaling in satellite cells, and
that (ii) the attenuation of TGF-b receptor engagement is
sufﬁcient to restore myogenic responses in old cultures. TGF-b
receptor levels in satellite cells increase approximately three to
fourfold with age (Supporting Fig. S6A), suggesting a com-
pounding effect on signaling from an age-dependent elevation
of ligand (Carlson et al., 2008) and receptor. In this regard, we
compared the intensity of TGF-b signaling, and the efﬁciency of
myogenic responses, in satellite cells expressing a TGF-b domi-
nant-negative receptor II (TGF-b DN RII), compared to control
vector (Tang et al., 1999; Yu & Schaffer, 2006). Young and old
satellite cells were activated by muscle injury, followed by pro-
genitor cell isolation and retroviral transduction with TGF-b DN
RII or control vector, ex vivo. The dominant-negative TGF-b
receptor is an inactive kinase, which effectively inhibits signaling
by active TGF-b ligands (Tang et al., 1999). As shown in Fig-
s 4A,B and S6B, while having no effect on satellite cells cultured
(A)
(B)
(C)
Fig. 4 Down-modulation of transforming growth factor (TGF)-b signaling intensity by dominant negative TGF-b RII attenuates old sera-imposed satellite cell
regenerative potential inhibition. (A) Young and old mice were injured with CTX, as described; bulk myoﬁbers with activated satellite cells were then explanted
and transiently transduced with a TGF-b RII DN-expressing lentivirus, or control virus, in vitro. Following transduction, myoﬁber-derived cells were cultured for 48 h
in OPTI-MEM + 5% young (YS) or old (OS) mouse serum. Cells were ﬁxed and analyzed by immunoﬂuorescence for the expression of desmin (green), and levels of
BrdU incorporation (red). Hoechst (blue) labels all nuclei. The successful down-modulation of TGF-b signaling by DN RII virus provided restoration of satellite cell
regenerative potential in cells exposed to old serum, as evidenced by large number of de-novo proliferating desmin
+ myoblasts that form multinucleated
myotubes. Bar = 50 um. (B) Quantiﬁcation of regenerative potential shown in A, The percent of desmin+ ⁄BrdU+ cells is shown as means with standard
deviations. (*) indicates P < 0.05, compared to treatment with young serum and control virus (Y serum + cntl.) (**) indicates P < 0.05, as compared to treatment
with old serum and control virus (O serum + cntl.). (C) Levels of nuclear P-Smad3 were diminished in old satellite cells transduced with DN RII-expressing lentivirus,
in vitro. Old satellite cells, exposed to old serum (OS) plus control virus, or old serum plus DN RII-expressing virus (as indicated), were immunostained for P-Smad3
(green). Hoechst (blue) labels nuclei. As expected, levels of satellite cell nuclear P-Smad3 were diminished in cells transduced with DN RII-expressing virus, as
compared to control (white arrow). Bar = 25 lm.
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681with young serum, TGF-b DN RII expression rescued myogenic
proliferation and differentiation in the presence of old serum.
The age-related differences in TGF-b signaling strength, and the
attenuation of TGF-b signaling DN RII expression, were con-
ﬁrmed by nuclear P-Smad3 analysis in muscle cells (Fig. 4C).
Ectopic expression of truncated TGF-b DN RII was conﬁrmed by
Western blot (Supporting Fig. S6C).
Systemic delivery of a TGF-b receptor inhibitor (but
not anti-TGF-b antibody or soluble TGF-b receptor)
restores old muscle repair, in vivo
Examinationofourdatasuggestedthatsera-derived TGF-b1was
released by platelets during collection procedures. Nevertheless,
it remained possible that plasma-based endocrine TGF-b1 could
play a role in the inhibition of satellite cells. To examine potential
age-dependent endocrine affects of TGF-b1, and to distinguish
them from its local inﬂuences, we sought to rejuvenate aged
muscle repair by attenuating the TGF-b pathway through sys-
temic pharmacological intervention, in vivo. Three independent
attenuators were used in these experiments: (i) a small molecule
inhibitor of TGF-b RI kinase (Singh et al., 2003; Gellibert et al.,
2004),(ii)TGF-bneutralizing antibodyand(iii)adecoycomposed
of the extracellular portion of TGF-b receptor II. These molecules
were systemically administered for 10 days, followed by cardio-
toxin (CTX) muscle injury. Samples were harvested at 5 days
postinjury, and examined histologically. The efﬁciency of adult
myogenesis, and age-related changes in this process, were reli-
ably determined by the detection and quantiﬁcation of newly
formed myoﬁbers. Such de novo ﬁbers are characteristically
small, express eMyHC and have centrally located BrdU
+ nuclei –
indicating that these cells were recently generated by proliferat-
ing, fusion-competent myoblasts (Wagers & Conboy, 2005;
Carlson & Conboy, 2007a; Carlson et al., 2008). Newly formed
muscle ﬁbers are typically numerous and visible in young regen-
erating muscle, but less numerous in old muscle, which instead
showsmoremononucleatedcellsandscarformation(Fig. 5A).
Muscle regeneration from mice treated by systemic adminis-
tration of the TGF-b RI kinase inhibitor was signiﬁcantly
improved, and similar to the regeneration seen in young control
animals (Fig. 5A,B), or young animals receiving TGF-b RI kinase
inhibitor treatment (Supporting Fig. S7A–D). In contrast, sys-
temic administration of either TGF-b neutralizing antibody, or
soluble TGF-b receptor II, failed to improve myogenic regenera-
tive capacity in old mice (Fig. 5A,B). To control for the biological
activity of the anti-TGF-b neutralizing antibody, we performed
intra-muscular injections [which enhanced old muscle repair as
expected (Supporting Fig. S7E,F)]. In agreement with the data
shown in Figs 3 and S5, experimental attenuation of Wnt (by
FRP) did not improve the regeneration of old muscle, in vivo. Fur-
ther, Wnt attenuation did not synergize with intra-muscular
attenuation of TGF-b, which alone sufﬁced for the rescue of old
muscle repair (Supporting Fig. S7E,F).
To control for potential half-life differences of the anti-TGF-b
neutralizing antibody, compared to TGF-b RI kinase inhibitor,
we also employed osmotic subcutaneous pumps for the constit-
utive systemic delivery of these molecules. Under these condi-
tions, the anti-TGF-b neutralizing antibody still failed to
signiﬁcantly enhance repair of old muscle, while TGF-b RI kinase
inhibitor robustly promoted muscle repair (Fig. 5B). These key
data suggest that endocrine TGF-b1 does not play a major role
in the age-related decline of muscle regeneration, in vivo.
Furthermore, ELISA assays on systemic TGF-b1 levels not only
corroborated, but strengthened this conclusion (Fig. 6A). These
data demonstrated that TGF-b1 neutralizing antibody, or soluble
TGF-b receptor II, failed to reduce circulating levels of TGF-b1i n
old mice (Fig. 6A). In agreement with other reports, our ﬁndings
suggest that bio-active TGF-b1 is not present in the circulation,
which would be recognizable by the herein tested antibody or
cognate receptor (Annes et al., 2003; Hyytiainen et al., 2004;
Feng & Derynck, 2005).
The rejuvenating effects produced by TGF-b RI kinase inhibitor
systemic delivery are best explained by the attenuation of local
TGF-b signaling in all tissues, including skeletal muscle. As
shown in Fig. 6B,C, this hypothesis is directly substantiated by
our experimental data. Namely, the high levels of P-Smad3 and
TGF-b1, typical of old muscle (Carlson et al., 2008), are signiﬁ-
cantly reduced in old mice receiving systemically administered
TGF-b RI kinase inhibitor, but not in old mice receiving anti-
TGF-b antibody or soluble receptor. Importantly, osmotic pump
delivery TGF-b RI kinase inhibitor not only reduced P-Smad3
levels, but also diminished levels of TGF-b1 production by
muscle cells, suggesting positive feed-back regulation in the
TGF-b pathway (Fig. 6B,C).
Together, these data establish that systemically administered
TGF-b RI kinase inhibitor acts locally to attenuate TGF-b1⁄
P-Smad3 signaling in satellite cells, and restores muscle repair, in
vivo. These ﬁndings are also in agreement with our previous
report (Carlson et al., 2008). In contrast, systemic levels and
intra-muscular TGF-b1 signaling strength are not down-
modulated, and old muscle repair is not enhanced by circulating
neutralizing antibody or soluble receptor (which do not access
endocrine or tissue TGF-b when administered systemically).
Thus, while TGF-b1 is released by platelets during sera collec-
tion, and does exhibit an inhibitory and age-dependent inﬂu-
ence on satellite cells, in vitro (Figs 1, 2 and S2), there is no
evidence for TGF-b1 endocrine anti-myogenic activity, in vivo.
Discussion
The data presented in this work establish the anti-regenerative
properties and inhibitory range of TGF-b1. These data also dem-
onstrate that the age-related increase in TGF-b1 levels is con-
served between mouse and human sera (Figs 1 and 2), and may
therefore be universal to the aging process of mammals. In our
studies, there was less variation in measurable TGF-b1 levels
within mice (when compared with humans), likely owing to their
environmental and genetic homogeneity. It is also important to
note that our reported human TGF-b1 levels are representative
of the healthy aging population, as individuals for these studies
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682were prescreened for confounding medical conditions. Despite
this, none of the aged individuals (‡ 60 years) had less than
measurable levels of TGF-b1, as opposed to many of the young
individuals (£ 30 years) enrolled in these studies. Considering
that TGF-b1 is broadly produced, and signals to a variety of cells,
the age-related and evolutionarily conserved elevation of its
functional levels in old sera may affect stem cell responses in var-
ious other tissues. Such a ﬁnding may provide a preliminary
explanation for the general organ stem cell regenerative poten-
tial decline of mice and humans.
With respect to satellite cell activation, TGF-b1 operates in a
threshold fashion (Fig. 1), and appears to function through the
TGF-b II receptor and P-Smad signaling (Figs 4 and 6). Our ﬁnd-
ings suggest that certain levels of TGF-b1 are actually required
for normal satellite cell responses (Fig. 1). Experimental down-
modulation of this pathway is therefore expected to be typically
harmful, unless it is transient (Figs 1, 4––6) or performed to pre-
cise ‘beneﬁcial’ levels. These conclusions ﬁt well with studies,
reporting that among other important functions, TGF-b1 signal-
ing is needed for efﬁcient immune cell and wound clearance
responses (Dunker & Krieglstein, 2000). TGF-b proteins have
been shown to behave as morphogens which, depending on
concentration, induce various gene subsets and promote differ-
ent effects (McPherron et al., 1997; Itoh et al., 2003; Kamanga-
Sollo et al., 2003; Muller et al., 2003; Wharton et al., 2004).
The morphogenic nature of the TGF-b family agrees with our
conclusion that, at speciﬁc concentrations, TGF-b1 is permissive
or nonpermissive to productive myogenic regenerative
responses (Figs 1, 2 and S1, S2). Consequently, pronounced
down-modulation of TGF-b1 causes immune disorders, inﬂam-
mation and organ dysfunction. This complicates the use of
TGF-b1 attenuators, such as antibodies and small molecules
(delivered by pumps, or otherwise), or the use of genetically
altered mice, which do not survive into old age if they harbor
TGF-b pathway insufﬁciencies. For example, genetic deﬁciencies
in TGF-b1,2,3, TGF-b RI,II,III, Smad2, Smad4 and others (Oshima
et al., 1996; Bonyadi et al., 1997; Larsson et al., 2001; Brionne
et al., 2003; Andrews et al., 2006) all cause embryonic or
(A)
(B)
Fig. 5 Systemic pharmacological intervention
lowers sera transforming growth factor (TGF)-b
levels and improves regeneration in old animals.
Old or young mice were injected (subcutaneous)
with a small molecule inhibitor of the TGF-b RI
kinase (Ki), for 2 weeks. Five days before the end of
treatment, muscle was injured as described. At the
end of treatment, animals were sacriﬁced and
muscle was collected. BrdU was injected
(intraperitoneal) at 3 days postinjury to label
proliferating, fusion-competent myoblasts. (A)
Cryosections (10 lm) were performed in young
and old muscle (receiving vehicle alone), old + Ki
and old + RII (extracellular portion of TGF-b
receptor II). Sections were analyzed by
hematoxylin ⁄ eosin (H&E) staining and
immunostaining for both embryonic myosin heavy
chain (eMyHC, shown in green) and BrdU
incorporation (shown in red). Hoechst stains nuclei
(blue). As shown, the regenerative outcome of old
and old + RII was worse than young (judged by
scar tissue formation, de novo myoﬁber
size ⁄ scarcity and reduction of BrdU
+ nuclei within
eMyHC ﬁbers). Scale bar = 100 lm. In contrast,
muscle repair was improved by treatment with
TGF-b RI kinase (Ki) small molecule inhibitor (similar
to young with respect to large ⁄ dense eMyHC
+
myoﬁbers with centrally located BrdU
+ nuclei). (B)
Regeneration was quantiﬁed from muscle sections,
and is presented as mean percent of newly
regenerated myoﬁbers per square millimeter of
injury site. Error bars indicate SD, n =3 ,* P = 0.01
between young or old +Ki, and old.
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683neonatal lethality, due to the abnormal development of various
organ systems. Furthermore, Smad3 knockout animals survive
after birth, but die before old age due to chronic infections,
accelerated rate of cancers and T-cell dysfunction (Datto et al.,
1999; Yang et al., 1999). TGF-b1 heterozygous mice also sur-
vive after birth, but have increased neuronal abnormalities,
inﬂammation and ﬁbrosis of blood vessels (Wyss-Coray et al.,
1997, 2001; Brionne et al., 2003). Combined, these data agree
with our conclusion that prolonged, or sustained, experimental
down-modulation of TGF-b1 levels will perturb cellular function.
Our work reveals that platelet-derived sera TGF-b1 levels, or
endocrine TGF-b1 levels, do not explain the age-dependent inhi-
bition of tissue regeneration by this cytokine. Speciﬁcally, if all
endogenous young sera TGF-b1 were active, it would readily
suppress satellite cell responses, in vitro (Figs 1 and 2). Further,
neutralization of circulatory TGF-b1 is not achievable by experi-
mental ligand traps, in vivo (Figs 5 and 6). These data suggest
the presence of a natural TGF-b1 modiﬁer⁄decoy (predictably
more active in the young), which is likely endocrine in nature, or
released during platelet activation (Figs 1 and 2). Future work
on the characterization of such natural systemic antagonist(s) of
TGF-b1 may also explain the regenerative phenotypes observed
in hetereochronic parabiosis (Conboy et al., 2005).
This work further conﬁrms and extrapolates the auto-
crine⁄paracrine mode of TGF-b age-dependent inhibition of
organ stem cell responses (Carlson et al., 2008). Speciﬁcally, old
tissue repair was improved only when P-Smad3 levels were
attenuated locally in muscle (e.g. through small molecule
systemic delivery), which is also expected to attenuate TGF-b
signaling broadly in all tissues (Figs 5 and 6). In contrast, systemi-
cally administered neutralizing antibody, or soluble receptor,
failed to restore old muscle repair. These molecules did not
attenuate endocrine or local TGF-b1, nor diminish P-Smad3
levels in satellite cells, in vivo (Figs 5 and 6). These data also
predict the presence of a positive feed-back loop, where a
certain TGF-b signaling strength is required to maintain TGF-b1
ligand expression (Fig. 6), which was additionally suggested by
TGF-b level reduction in muscle treated with RNAi to Smad3
(Carlson et al., 2008). It remains to be determined whether
there is a broad TGF-b1 increase within old tissues (in addition to
skeletal muscle ﬁbers), or if a narrow subset of cells in aged
organisms overproduce TGF-b1.
While the involvement of additional TGF-b family members
(or other age-dependent cytokines involved with muscle repair
decline) is certainly not ruled out, TGF-b1 was identiﬁed here as
a key, age-related inhibitor of myogenic responses. Additionally,
myostatin was previously reported to not locally increase in old
muscle tissue (Carlson et al., 2008), thus implicating the ubiqui-
tous TGF-b1, rather than tissue-speciﬁc family members in these
age-related phenotypes. While other circulatory molecules may
contribute to the aging of muscle stem cell responses, our data
suggest that Wnt is not a systemic age-dependent attenuator of
myogenicity (Figs 2, 3, S2 and S4). These data are in apparent
disagreement with those reported by Brack et al. (2008); and
further study will resolve whether Wnt is present in the circula-
tion, is upregulated with aging and becomes inhibitory to myo-
genic responses at some age-speciﬁc level. Of note, in reports
examining Wnt in young mice only, it is suggested that Wnt
(B)
(A)
(C)
Fig. 6 Systemic pharmacological intervention lowers sera transforming
growth factor (TGF)-b levels and improves regeneration in old animals.
(A) Myoﬁbers were isolated from young, old and old mice with indicated
treatments for TGF-b systemic down-modulation. Cell lysates were then
analyzed by Western blot for levels of secretory TGF-b and P-Smad3 signaling
strength. Actin immunodetection was used as a loading control. As expected,
higher levels of TGF-b and P-Smad3 were detected in old samples, as
compared to young. O + Ki pump showed reduction in both TGF-b and
P-Smad3, whereas O + Ki injection only reduced P-Smad3 signaling strength.
(B) Results of multiple Western blot assays were quantiﬁed (normalization of
TGF-b and P-Smad3 pixel density by actin-speciﬁc pixel density) and are
depicted by relative pixel intensity, as shown; (*) indicates P < 0.01, O Ki
compared to old and young. Error bars indicate SD. n = 3–4. (C) TGF-b levels
in serum for each animal in young, old or old + experimental treatments were
determined by ELISA. Shown are mean values with standard deviations
(n = 3–12, P £ 0.05 between O + Ki pump and O + anti-TGFb pump, and
O+K i⁄O + RII injection.
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684promotes satellite cell myogenicity for both differentiation of
myoblasts to myotubes, and with respect to satellite cell self-
renewal (Brack et al., 2008; Le Grand et al., 2009).
Comprehensively, these studies identify physiological sources
of TGF-b1 that are responsible for age-related muscle repair
inhibition, and point toward novel therapeutic strategies for the
enhancement of organ regenerative potential. In proof of princi-
ple research, intra-muscular attenuation of Smad3, by RNAi,
rescued aged muscle repair (Carlson et al., 2008). Such method-
ology, however, is not easily applicable to an organism-wide
restoration of old organ repair. In contrast, our herein reported
systemic delivery of a TGF-b receptor kinase inhibitor allows one
to reach all tissues, to recalibrate TGF-b1 ligand levels to their
youthful states and to potentially rejuvenate their regenerative
function.
Experimental procedures
Cell culture
Myoﬁber explant cultures and primary myogenic progenitor cells
were generated from C57⁄Bl6 mice as described previously
(Conboy et al., 2003). Myoblasts were maintained in growth
media (Ham’s F-10, 20% FBS, 5 ng mL
)1 basic-FGF and penicil-
lin–streptomycin). Opti-MEM was used to culture myoﬁber
explants in 10% young, 10% old or 10% young plus old mouse
serum (5% each). Differentiation media consisted of DMEM and
5% horse sera. Basic-FGF was obtained from Sigma (St Louis,
MO, USA) and R&D systems (Minneapolis, MN, USA), Opti-MEM
was obtained from Invitrogen (Carlsbad, CA, USA), and all other
cell culture reagents were obtained from Cellgro (Herndon, VA,
USA).
Retrovirus production and transfection
pMSCV-TbRIIDN retroviral vector was a kind gift from Dr Chung
Lee (Kundu et al., 2000; Shah et al., 2002). TbRIIDN was excised
from the vector using EcoRI⁄BamHI, blunted with Klenow (NEB)
and inserted into the MoMLV retroviral vector pCLPCGFP
(Ignowski & Schaffer, 2004). pCLPCGFP was ﬁrst digested with
BamHI, following which it was also blunted with Klenow and
ligated with the TbRIIDN fragment. The resulting pCLPC TbRIIDN
vector was sequenced to conﬁrm its sequence and directionality
of insertion. A plasmid made by ligating the blunt ends of the
pCLPC vector was used as a control. To produce retrovirus, HEK
293T cells (cultured in Iscove’s modiﬁed Dulbecco’s medium
(Hyclone, Logan, UT, USA) with 10% fetal bovine serum (Invitro-
gen) and 1% penicillin–streptomycin (Gibco, Carlsbad, CA,
USA) and maintained at 37  C and 5% CO2) were co-transfect-
ed with the retroviral vector (pCLPC TbRIIDN or control plasmid)
and the helper plasmids pCMV-VSVG, a vector encoding the
viral envelope protein from the vesicular stomatitis virus and
pCMV-gagpol, a vector encoding the enzymatic and structural
retroviral proteins, using the calcium phosphate transfection
method as described (Yu & Schaffer, 2006). Medium was
changed 12 hours after transfection. Forty-eight hours after
transfection, the cell culture supernatant, containing the virus,
was collected and puriﬁed by ultra centrifugation through 20%
sucrose in phosphate-buffered saline (PBS) and resuspended in
PBS. The virus also encoded a gene that rendered it resistant
against puromycin, and was titered on 293T cells using WST1
reagent (Roche, Mannheim, Germany) following the manufac-
turer’s protocol.
Viral transduction was performed on bulk myoﬁber ex-
plants with activated satellite cells, isolated 3 days postinjury
from CTX-injured young and old animals. Cells were
infected with TbRIIDN (2 · 10
6 TU mL
)1), or control viruses (1 ·
10
7 TU mL
)1), at assay-dependent MOIs, and cultured for
48 hours in the presence of OPTI-MEM, +5% young or old
mouse serum prior to ﬁxation and analysis. No tetracycline was
added in these experiments.
Animal strains
Young (2–4 month) and old (20–24 month) C57⁄Bl6 male mice
were obtained from Jackson Laboratories (Bar Harbor, ME, USA)
and NIA (Bethesda, MD, USA) respectively.
Antibodies and reagents
Antibody against embryonic myosin heavy chain (develop-
mental) was purchased from Vector Laboratories (Burlingame,
CA, USA) and the Developmental Studies Hybridoma Bank.
Phosphorylated-Smad2⁄3 antibody [1:200 WB (Western blot),
1:100 IF (immunoﬂuorescence) was obtained from Chemicon
(Temecula, CA, USA) and Santa Cruz Biotechnologies (Santa
Cruz, CA, USA; sc-11769)]. Bioactivity neutralizing antibody
against TGF-b1( MAB240), rTGF-b1 (240-B) rWnt3a (1324-
WN) sFRP3 (592-FR) and huTGF-b RIII (242-R3) were purchased
from R&D Systems. Delta (9120) and TGF-beta receptor I
(SC 9048) (1:100 WB) antibodies were obtained from Santa
Cruz Biotechnologies. Activated Notch (1:500 WB) (ab8925)
and BrdU (1:100 IF) (ab6326) antibody were obtained from
Abcam (Cambridge, MA, USA). Desmin (1:25 IF) (clone DE-
U-10, #D1033) and actin (1:250 WB, A5060) antibodies were
purchased from Sigma.
Muscle injury
Isoﬂurane was used to anesthetize the animal during the muscle
injury procedure. For bulk myoﬁber satellite cell activation, tibial-
is anterior and gastrocnemius muscles were injected with CTX I
(Sigma) dissolved at 100 lgm L
)1 in PBS, at 2–5 sites for each
muscle for approximately 50 lLg
)1 muscle. Muscles were har-
vested 3 days later. For focal injury, to assay regeneration
in vivo, 2–3 lL of 1 mg mL
)1 CTX was injected at one site to the
middle of the tibialis anterior, or two sites at the gastrocnemius,
and muscle harvested 5 days later. In some experiments, FRP3
(500 ng), anti-TGF-b (10 ng), FRP3⁄anti-TGF-b or IgG (10 ng)
were injected intramuscularly into injury sites, 24 h following
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685initial injury. In these studies, BrdU (50 mg kg
)1) was injected IP
at 2 days following injury.
Immunoﬂuorescence and histological analysis
All muscle tissue was dissected, ﬂash frozen in OCT compound
(Tissue Tek; Sakura Finetek, Zoeterwoude, The Netherlands) and
cryo-sectioned at 8–10 lm, as previously described (Conboy
et al., 2003). Muscle sections were stained with aqueous hema-
toxylin and eosin (H&E), as per the manufacturer’s instructions
(Sigma-Aldrich). Regeneration and myogenic potential was
quantiﬁed by examining injury sites from representative sections
along the muscle (spanning the volume of injury), then measur-
ing the injured⁄regenerating area using Adobe Photoshop
Elements. In all experiments, regenerating tissue was obtained
from both tibialis anterior and gastrocnemius muscles. Cryo-
sectioning was performed through the entire volume of muscle
(typically 50–70 sections total, done at 200 lm intervals),
thereby serially reconstituting the entire tissue, ex vivo. Myoﬁber
regeneration was quantiﬁed by counting total newly regener-
ated ﬁbers at injury epicenters, per volume of injury (typically
1m m
2) and dividing ﬁbers per area. Immunostaining was
performed as described (Conboy et al., 2003). Brieﬂy, after
permeabilization in PBS + 1% FBS + 0.25% Triton-X-100,
tissues and cells were incubated with primary antibodies in
staining buffer (PBS + 1% FBS) for 1 h at room temperature,
followed by 1 h incubation ﬂuorochrome-labeled secondary
antibodies (ALEXA; Molecular Probes, Carlsbad, CA, USA at
1:1000). P-Smad2⁄3 and BrdU-speciﬁc immunostaining
required an extra step of 2 M HCl treatment (denaturation of
DNA) before permeablization. The index of myogenic potential
was evaluated, based on BrdU⁄eMyHC costaining, as previously
described (Carlson & Conboy, 2007a; Carlson et al., 2008).
Depletion of TGF-b from culture media
Opti-MEM containing either 10% young or old mouse serum
was incubated in the presence of 5 lgm L
)1 TGF-b antibody
(R&D Systems) overnight at 4  C. Protein-G agarose was then
added to the media⁄antibody mix and incubated for 4 h at
4  C. The mixture was then centrifuged at 10 000 RCF for
5 min. Supernatant was collected and centrifugation was
repeated. TGF-b depleted supernatant was used for culture.
Plasma⁄platelet preparation and activation of serum
TGF-b
For plasma preparation, < 100 lL was collected from the tail
into 10 lL of 100 mM EDTA. Red blood cells were removed by
sedimentation, twice at 150 g for 10 min, followed by platelet
sedimentation for 10 min at 1500 g. Platelet-poor plasma was
re-cleared by an additional sedimentation for 10 min at
1500 g. Platelets were washed once with 0.08 M sodium cit-
rate, pH 6⁄0.9 g L
)1 sodium chloride, sedimented again at
1500 g, and resuspended in cold water before ﬂash freezing.
Serum TGF-b was activated by mixing 100 lL of serum with
100 lL1 0 M Urea⁄2.5 M acetic acid, followed by incubation
for 10 min at room temperature. Acid treatment was neutral-
ized with 2.7 M sodium hydroxide⁄1 M HEPES, and salts were
removed via ultraﬁltration (Vivaspin 500, 3 kDa MWCO; GE
Healthcare, Piscataway, NJ, USA).
Measurement of bioactive levels of TGF-b in serum
Serum was isolated as previously described (Conboy et al.,
2003). Brieﬂy, blood cells were coagulated at 37 C for 15 min
and centrifuged to isolate serum. In the luciferase-reporter
trans-activation assay, the biological activity of TGF-b was
measured via induction of the PAI-1 promoter in mink lung
epithelial cells stably expressing a PAI promoter-luciferase con-
struct (Abe et al., 1994). Brieﬂy, 3 · 10
4 transfected cells
were plated in 96-well plates in 50 lL of Dulbecco’s modiﬁed
eagle medium (DMEM) with 0.5% fetal bovine serum and
incubated for 3 h at 37  Ci n5 %C O 2. Experimental sample
(50 lL of DMEM with young or old mouse serum at 1:2 and
1:10 dilutions) was added to triplicate wells and incubated for
16 h. Cells were then washed with PBS and lysed. The lucifer-
ase activity in the lysate was measured in an EG&G Berthold
Microlumat LB 96P (Oak Ridge, TN, USA) for 10 s, immedi-
ately following auto-injection of 20 lL of luciferase substrate
and recorded as relative light units integrated over time. A
TGF-b standard curve was performed to determine the total
amount of active TGF-b. Neutralizing antibodies speciﬁc for
individual TGF-b (R&D Systems) were added to demonstrate
speciﬁcity.
Measurement of bioactive levels of WNT in serum
L cells, stably harboring SuperTopFlash (Kaykas et al., 2004) and
pEF1-LacZ constructs (‘LSL cells’), were plated into 96-well
microtiter dishes at approximately 80–90% conﬂuency. After
6 h postplating, media was removed and LSL cells were trea-
ted with serum or Wnt protein diluted into complete media
(DMEM⁄10% FBS plus antibiotics) for approximately 16 h at
37  C luciferase activity was measured in a Lumat LB 9507 lumi-
nometer (Berthold) using the Dual light TROPIX kit according to
manufacturer’s instructions. All assays were performed in tripli-
cate, and the relative luciferase units were normalized to LacZ
readings.
Measurement of serum TGF-b levels
Mouse blood was collected upon euthanasia, and serum was
prepared as above. Mouse serum levels were determined by
sandwich ELISA, as per the manufacturer’s protocol (R&D Sys-
tems #DY1679), with the recommended pretreatment of sam-
ple with acid⁄urea, followed by neutralization. To avoid
dilution effects on measurement, peak readings calculated
from the corrected dilution curve were used for comparison
among samples. Serum from aged and young human subjects
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686was collected and stored in aliquots at )70  C until used.
Young donors were between 20 and 35 years of age and
elderly donors were between 65 and 90 years of age. Elderly
subjects belonged to middle-class socio-economic status, and
were living independently. This study was approved by the
Institutional Review Board of the University of California,
Irvine. Human TGF-b levels were determined using a speciﬁc
ELISA kit (BD Biosciences, San Jose, CA, USA) with the recom-
mended pretreatment of sample with acid, followed by neu-
tralization with the base.
Western blot analysis
Western blotting was performed according to standard proto-
cols. Typically, 30 lg of protein extract from myoﬁbers, or
satellite cells, were run on SDS–PAGE gels (Bio-Rad, Hercules,
CA, USA). Primary antibodies were diluted in 5% nonfat milk
in 1· PBS-T at indicated dilutions (see above). HRP-conjugated
secondary antibodies (Santa Cruz Biotech) were diluted
1:1000 in 1· PBS, 2%BSA, and 0.5% Tween-20. Nitrocellu-
lose membranes were treated with secondary antibodies for
1 h at room temperature, developed using ECL reagent
(Amersham, Sunnyvale, CA, USA), and imaged on a Bio-Rad
Chemidoc XRS.
Pharmacological intervention
For modulating TGF-b levels systemically, the TGF-b RI kinase
inhibitor (Calbiochem⁄EMD Chemicals Gibbstown, NJ, USA;
catalog # 616452) was delivered at 10 nmole over 2 weeks,
by injecting twice daily for 4 weeks (subcutaneous) with
100 lL of a 1:10 dilution of 3.4 mM inhibitor (dissolved in dim-
ethylsulfoxide), diluted in PBS with diluted DMSO as control.
Five days before the end of treatment, muscle was injured as
described. At the end of treatment, animals were sacriﬁced
and muscles were collected. BrdU was injected (intra-
peritoneal) at 3 days postinjury to label proliferating, fusion-
competent myoblasts.
Statistical analysis
A minimum of three replicates were performed for each experi-
mental condition. Quantiﬁed data are presented as means and
standard deviations. Analysis of variance was used to compare
data from different experimental groups. P-values of < 0.05
were considered statistically signiﬁcant.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Fig. S1 Time-course analysis of myogenic proliferation and
differentiation.
Fig. S2 Old serum inhibits myogenic differentiation by TGF-
b-dependent mechanism.
Fig. S3 Old animals have high levels of total platelet and bio-
active sera TGF-b.
Fig. S4 Old serum inhibits myogenic differentiation by a TGF-
b-dependent and Wnt-independent mechanism.
Fig. S5 Wnt does not reduce myogenic responses in young sera
and FRP does not rescue myogenic responses in old sera in single
myoﬁber systems.
Fig. S6 Old animals have high levels of TGF-b receptor expres-
sion; dominant negative TGF-b RII is expressed by virally infected
muscle stem cells.
Fig. S7 Systemic pharmacological intervention does not
adversely affect TGF-b sera levels and muscle regeneration in
young animals; Wnt down-regulation by FRP does not rescue
regeneration of old muscle, in vivo.
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